Drugs / VBI-2902a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04773665 | Mar 2021 → Nov 2022 | COVID-19 | VBI Vaccines Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-06-29 | VBI Vaccines Inc. | Results VBI Vaccines Announces Initial Positive Phase 1 Data for its eVLP Vaccine Candidate Against COVID-19 vbivaccines.com ↗
The 5µg dose of VBI-2902a, which expresses an optimized SARS-CoV-2 spike antigen and is adjuvanted with aluminum phosphate, was generally well-tolerated and elicited potent immune responses significantly higher than those seen in human convalescent sera. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-06-29 | VBI Vaccines Inc. | VBI Vaccines Announces Initial Positive Phase 1 Data for its eVLP Vaccine Candidate Against COVID-19 vbivaccines.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VBI-2902a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04773665 ↗ |